Chapter 3

Tyrosine Kinase Inhibitors; Therapies for Thyroid Cancer

Silvia Martina Ferrari, Poupak Fallahi, Enke Baldini, Salvatore Ulisse, Gabriele Materazzi, Paolo Miccoli and Alessandro Antonelli

Abstract

In spite of the good prognosis of thyroid carcinoma (TC), a metastatic disease is developed by approximately 5% of patients, not responsive to radioactive iodine (RAI), and with a more aggressive behaviour. The absence of specific and effective drugs for aggressive TC leads to the need of new efforts towards new drugs development. </p><p> Several genetic alterations in different molecular pathways in TC have been shown in the last decades, associated with TC development and progression. Rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, RET mutations, BRAF mutations, RAS mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways are some of the studied pathways, determinant in TC development. Tyrosine kinase inhibitors (TKIs) are small organic compounds inhibiting tyrosine kinases auto-phosphorylation and activation, most of them are multikinase inhibitors. TKIs act on the above-mentioned molecular pathways involved in growth, angiogenesis, local and distant spread of TC. TKIs are emerging as new therapies of aggressive TC, including differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC), and they have been shown capable of inducing clinical responses and stabilization of disease. Vandetanib and cabozantinib have been approved for MTC treatment; sorafenib and lenvatinib have been approved for DTC refractory to RAI. These drugs prolong median progression-free survival, but until now no significant increase has been observed on overall survival; side effects are common. New efforts are made to find new more effective and safe compounds, and to personalize the therapy in each TC patient.

Total Pages: 47-61 (15)

Purchase Chapter  Book Details